Cadrenal Therapeutics, Inc.
CVKD
$10.51
$1.6518.62%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -23.02% | 17.82% | |||
| Depreciation & Amortization | 0.00% | -92.73% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.79% | -4.93% | |||
| Operating Income | 26.79% | 4.93% | |||
| Income Before Tax | 26.77% | 4.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 26.77% | 4.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 26.77% | 4.63% | |||
| EBIT | 26.79% | 4.93% | |||
| EBITDA | 26.80% | 4.81% | |||
| EPS Basic | 29.72% | 10.35% | |||
| Normalized Basic EPS | 29.72% | 10.35% | |||
| EPS Diluted | 29.72% | 10.35% | |||
| Normalized Diluted EPS | 29.72% | 10.35% | |||
| Average Basic Shares Outstanding | 4.20% | 6.37% | |||
| Average Diluted Shares Outstanding | 4.20% | 6.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||